Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study)

Acta Neurol Scand. 2006 Sep;114(3):181-6. doi: 10.1111/j.1600-0404.2006.00703.x.


Objectives and methods: This study investigated the ease with which 52 Parkinson's disease patients already receiving adjunct entacapone to traditional levodopa were switched to Stalevo (levodopa/carbidopa/entacapone).

Results: The switch to Stalevo was straightforward for most patients taking standard-release levodopa with 86% of these patients being able to replace their entire regimen without having to change the amount of levodopa taken. The majority of patients (54%, P = 0.162) preferred Stalevo; 31% preferred their prior treatment regimen; 15% had no preference. Patients found Stalevo more simple to dose (94%), more convenient to use (84%), easier to handle (84%), easier to remember (67%) and easier to swallow (59%), compared with their previous medication.

Conclusions: Stalevo was well tolerated, with a low incidence of adverse events. The study shows that Stalevo is an effective, preferred and well-tolerated means of delivering levodopa/carbidopa/entacapone in one easy-to-use tablet.

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / administration & dosage*
  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Carbidopa / administration & dosage*
  • Catechols / administration & dosage*
  • Cross-Over Studies
  • Drug Combinations
  • Female
  • Humans
  • Levodopa / administration & dosage*
  • Male
  • Middle Aged
  • Nitriles
  • Parkinson Disease / drug therapy*
  • Patient Satisfaction*
  • Treatment Outcome


  • Antiparkinson Agents
  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Catechols
  • Drug Combinations
  • Nitriles
  • Stalevo
  • Levodopa
  • entacapone
  • Carbidopa